Under one in 10 patients that would benefit from weight-loss injections such as Wegovy can access them, warns the global health agency as it publishes its inaugural recommendations on the drugs.
Given over a billion individuals worldwide currently living with obesity, it is advocating for more widespread and fairer access to these injectable treatments.
According to forecasts, more than two billion could be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the treatments that can aid individuals in losing substantial body mass, says the body.
Skinny Jab Shortage
Even under the current most optimistic case, the production of such drugs could only cover around 100 million people – under 10% of the global need, as stated by the health organization.
The advice urges countries and companies to increase access, by measures including licensing agreements.
Exclusive production rights on a key compound – the core component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Jabs Work
These medications mimick a body's own hormone to slow digestion, suppress the appetite and enhance feelings of fullness so users eat less.
People commonly begin shedding pounds after several weeks of commencing the regular doses.
Research indicates people may regain a significant portion a year later of halting the treatment, when their typical hunger resume.
To be overweight or obese elevates your likelihood for contracting medical conditions, including diabetes, heart disease, stroke, and certain malignancies.
Obesity affects individuals in countries worldwide and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
